(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Design Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast DSGN's revenue for 2025 to be $2,741,666,972, with the lowest DSGN revenue forecast at $2,741,666,972, and the highest DSGN revenue forecast at $2,741,666,972. On average, 1 Wall Street analysts forecast DSGN's revenue for 2026 to be $6,628,472,816, with the lowest DSGN revenue forecast at $6,628,472,816, and the highest DSGN revenue forecast at $6,628,472,816.
In 2027, DSGN is forecast to generate $11,568,896,815 in revenue, with the lowest revenue forecast at $11,568,896,815 and the highest revenue forecast at $11,568,896,815.